BGM — BGM Group Ltd.

Nasdaq · Health Care · Pharmaceuticals · CIK 1779578 · China
Last close
$0.31
Market Cap
$56.35M
52W High
$1.24
52W Low
$0.26
ADV30
270,261
Next earnings
BGM Group Ltd., through its subsidiaries, operates as a pharmaceutical and chemical company in China. It offers oxytetracycline products, including Qilian Shan oxytetracycline tablets to prevent and treat a range of diseases in chickens, turkeys, cattle, swine, and human; and Qilian Shan oxytetracycline active pharmaceutical ingredients, which are used by pharmaceutical companies in the manufacturing of medications that use oxytetracycline as an active ingredient. The company also provides licorice products, such as Gan Di Xin, a medicine made from raw licorice materials; Qilian Shan licorice extract, an ingredient for pharmaceutical companies to manufacture traditional licorice tablets; and Qilian Shan licorice liquid extract, an ingredient for medical preparation companies to produce compound licorice oral solutions. In addition, it offers traditional Chinese medicine derivatives products comprising Ahan antibacterial paste that is used to treat refractory chronic skin diseases; heparin products, including heparin sodium preparation, an ingredient for pharmaceutical companies to produce medications used in treating cardiovascular diseases, cerebrovascular diseases, and hemodialysis; and sausage casings, such as Zhu Xiaochang sausage casings for culinary purposes. Further, the company provides Fertilizer products comprising Xiongguan organic fertilizers to improve crop yield, increase soil's chemical properties, and reduce soil compaction; and Xiongguan organic-inorganic compound fertilizers for plant growth. Additionally, it focuses on the AI-driven commercialization of DuXiaoBao platform. BGM Group Ltd. is based in Chengdu, China.

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGrossProfit OpIncomeNetIncomeAssets CashLiabilities
Mar 2025 207,393,449 9,651,606 23,902,462
Sep 2024 53,003,728 9,817,254 8,910,379

Balance + Analyst (yfinance extras)

Retained Earnings
$3,488,157
Inventory
$8,848,748
Receivables
$16,832,902
ST Investments
$4,890,180
EBIT TTM
Pretax Income TTM
Interest Exp TTM
Analysts

Annual Trend (SEC EDGAR, last 3y)

Revenues vs Net Income (last 3y)

FY endRevenuesOpIncome NetIncomeAssetsLiabilities EquityOCF
Sep 2024 25,097,951 -357,356 -1,442,830 53,003,728 8,910,379 544,238
Sep 2023 46,471,478 -2,417,724 -7,780,620 51,257,994 6,906,593 312,209
Sep 2022 64,855,025 2,515,720 1,076,693 64,526,617 9,563,081 12,654,188

Peers — same industry

TickerNameMarket CapLastDaily %
HYPD HYPERION DEFI, INC. $56.08M $3.70
IBO IMPACT BIOMEDICAL INC. $55.20M $0.51
PROCF Sofgen Pharma S.A. $58.18M $0.03
SCYX SCYNEXIS INC $54.10M $0.68
KZR Kezar Life Sciences, Inc. $53.86M $7.29

News headlines (Yahoo Finance, 1h cache)

BGM Group Ltd. Receives NASDAQ Notice Related to Late Filing of Form 20-F
2026-02-26 21:15 · Yahoo
BGM Group Ltd. (BGM) Surges 35% as AI, Biopharma Transformation Gains Investor Attention
2025-10-01 17:41 · Yahoo
BGM To Report First Half 2025 Unaudited Financial Results on July 24, 2025
2025-07-23 10:36 · Yahoo
BGM Group Ltd.'s (NASDAQ:BGM) top holders are insiders and they are likely disappointed by the recent 8.4% drop
2025-06-29 14:30 · Yahoo
From Virtual Agents to Embodied and Industry-Specific AI: BGM Acquires Xingdao Intelligent and YD Network, Advancing AI on Two Fronts
2025-05-28 20:30 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.